Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Endothelium; Liver; Lung; Fibrinolysis; Plasminogen activator inhibitor-1;
مقالات ISI ترجمه شده مهار کننده فعال کننده پلاسمینوژن-1
مقالات ISI مهار کننده فعال کننده پلاسمینوژن-1 (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Tejido adiposo epicádico; Inhibidor del activador del plasminógeno tipo-1; Obesidad; Epicardial adipose tissue; Plasminogen activator inhibitor-1; Obesity;
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Saliva; Obesity; Oral health; Cytokines; Biomarkers; API; approximal plaque index; AUC; area under the curve; BMI; body mass index; CAL; clinical attachment level; CRP; C-reactive protein; DMF-S; caries prevalence index (decayed, missing, and filled surfa
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; ATII; alveolar epithelial type II; AIIt; annexin A2 heterotetramer; APC; activated protein C; BALF; broncho-alveolar lavage fluid; DAD; diffuse alveolar damage; EGF; epidermal growth factor; ECM; extracellular matrix; FAK; focal adhesion kinase; FV; facto
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; adolescent; type 2 diabetes mellitus; lipids; insulin; inflammatory markers; apoB; Apolipoprotein B; BMI; Body mass index; HbA1c; Glycated hemoglobin A1c; HDL-C; High-density lipoprotein cholesterol; hs-CRP; High-sensitivity C-reactive protein; IL-6; Inte
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Adipose tissue; Cancer associated adipocytes; FABP4; FABP5; Lipid metabolism; ADF; adipocyte-derived fibroblasts; BAT; brown adipose tissue; BMAT; bone marrow adipose tissue; BMI; body mass index; CAA; cancer-associated adipocytes; CAF; cancer-associated
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; IFN; interferon; TMA; thrombotic microangiopathy; HUVECs; human umbilical vein endothelial cells; IFNAR; IFN-α/β receptor; JAKs; Janus kinases; STAT; signal transducer and activator of transcription; mAb; monoclonal antibody; VEGF; vascular endothelial
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; aCL; anticardiolipin; ADP; adenosine diphosphate; APOH; apolipoprotein H; APS; antiphospholipid syndrome; β2GPI; β2-glycoprotein I; DVT; deep vein thrombosis; FDR; false discovery rate; GO; gene ontology; IL; interleukin; IRAK 1; interleukin-1 receptor-
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; aPTT; activated partial thrombosplatin time; BMI; body mass index; FMD; flow-mediated dilation; HDL-c; high density lipoprotein cholesterol; LDL-c; low-density lipoprotein cholesterol; MMP-9; matrix metalloproteinase-9; OSI; oscillatory shear index; OSS;
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; AWT; Anterior wall thicknesses; BW; Body weight; CO; Cardiac output; DCM; Diabetic cardiomyopathy; DM; Diabetes mellitus; ECL; Enhanced chemiluminescence; EDP; End diastolic pressure; EF; Ejection fraction; HF; Heart failure; HR; Heart rate; HFD; High-fat
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; High-sucrose diet; Adiposity; Lewis lung carcinoma; Metastasis; Mice; HF; high-fat; HOMA-IR; homeostatic model assessment of insulin resistance; HS; high-sucrose; LLC; Lewis lung carcinoma; MCP-1; monocyte chemotactic protein-1; PAI-1; plasminogen activat
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Plasminogen activator inhibitor-1; Coronary artery disease; Percutaneous coronary intervention; Biomarker; Stent thrombosis; In-stent restenosis;
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; ADP; adenosine diphosphate; Apo; apolipoprotein; AT III; antithrombin III; AUC; area under the curve; BMI; body mass index; CET; cholesterol ester transfer; CRP; C-reactive protein; CVD; cardiovascular disease; FMD; flow mediated dilation; FVII; factor VI
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; HA; hyaluronic acid; Tregs; regulatory T cells; T1DM; type 1 diabetes mellitus; IBD; inflammatory bowel disease; RA; rheumatoid arthritis; MHC; major histocompatibility complex; HLA; human leukocytes antigens; TLRs; toll-loke receptors; PRRs; pattern reco
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; AU; absorbance units; AU*min; aggregation units x minute; CI; confidence interval; CIHF; chronic ischaemic heart failure; IHD; ischaemic heart disease; PAI-1; plasminogen activator inhibitor-1; RIC; remote ischaemic conditioning; sP-selectin; soluble plat
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Asthma; Chronic rhinosinusitis; Fibrin; Nasal polyps; Nattokinase; CRS; Chronic rhinosinusitis; CRSwNP; CRS with nasal polyps; CRSsNP; CRS without nasal polyps; NK; Nattokinase; t-PA; tissue plasminogen activator; PAI-1; plasminogen activator inhibitor-1;
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Three-dimensional culture; Cell encapsulation; Conformal coating; Hydrogel; Gene therapy; Trophic factors; 2D; Two-dimensional; 3D; Three-dimensional; ALG; alginate; CCE; conformal coating encapsulation; DTT; dithiothreitol; dVS; divinyl sulfone; EGF; epi
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; CVD; cardiovascular disease; CAD; coronary artery disease; T2DM; type II diabetes mellitus; ACEIs/ARBs; angiotensin converting enzyme inhibitors/angiotensin receptor blockers; RAAS; renin-angiotensin-aldosterone system; VSMC; vascular smooth muscle cell;
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; 1-OHP; 1-hydroxypyrene; 3-NT; 3-nitrotyrosine; 8-oxodGuo; 8-oxo-7,8-dihydro-2'-deoxyguanosine; 15-F2t-IsoP; 15-F2t-isoprostane; +dP/ dt; rate of change of pressure development; -dP/dt; rate of change of pressure decay; Ach; acetylcholine; p-AKT; phospho
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Peritoneal adhesions; Adenovirus gene therapy; Matrix metalloproteinase-9; Tissue plasminogen activator; Plasminogen activator inhibitor-1; Transforming growth factor beta-1
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; BMI; body mass index; CI; confidence interval; CRP; C-reactive protein; CVD; cardiovascular disease; ET-1; endothelin-1; GCSF; Granulocyte-colony stimulating factor; IL-1b; interleukin-1b; IL-6; interleukin-6; IL-8; interleukin-8; IL-10; interleukin-10; M
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Bone marrow mesenchymal stem cells; Diabetic nephropathy; Renal fibrosis; Plasminogen activator inhibitor-1; Transforming growth factor-β1/Smad3 signaling pathway;
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; RIC; remote ischaemic conditioning; t-PA; tissue plasminogen activator; PAI-1; plasminogen activator inhibitor-1; eGFR; estimated glomerular filtration rate; CT; clotting time; CFT; clot formation time; MaxVel; maximum velocity; t, MaxVel; time to maximum
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Korean mistletoe; Chemotaxonomy; Glycone; Oleanolic acid; Plasminogen activator inhibitor-1; Vicenin-2 (PubChem CID: 442664); Peltatoside (PubChem CID: 5484066); Rhamnetin-3-O-rhamnoside (PubChem CID: 5491382); Oleanolic acid (PubChem CID: 10494);
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; ANS; autonomic nervous system; BP; blood pressure; CNS; central nervous system; CRP; C-reactive protein; DVT; deep venous thrombosis; FMD; flow mediated dilation, a marker of vascular regulation; HR; heart rate; IL-6; interleukin 6; NAAQS; Clean Air Act's
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; ACS; acute coronary syndrome; ACC; American College of Cardiology; AHA; American Heart Association; BMI; body mass index; CVD; cardiovascular disease; CI; confidence interval; CRP; C-reactive protein; Fib; fibrinogen; HDL-C; high-density lipoprotein chole
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; AA; arachidonic acid; ABCA1; adenosine triphosphate-binding cassette transporter A1; ACE-I; angiotensin-converting enzyme inhibitor; ACSL1; acyl-CoA synthase 1; ADMA; asymmetric dimethylarginine; Akt; protein kinase B; Aldo; aldosterone; AMPK; adenosine m
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; A-ADSCs; Apoptotic adipose stem cells; ACE; Angiotensin-converting enzyme.; ADSCs; Adipose-derived mesenchymal stem cells; AFSCs; Amniotic fluid stem cells; AKI; Acute kidney injury; ALF; Acute liver failure; ALI; Acute lung injury; ALT; Alanine transamin
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; AMPK; adenosine monophosphate-activated protein kinase; ASD; autism spectrum disorder; BBB; blood-brain barrier; CVD; cardiovascular disease; CDI; Clostridium difficile infection; CD; Crohn's disease; DSS; dextran sulphate sodium; eCB; endocannabinoid; Fi
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Interdisciplinary Research; Renal Fibrosis; Interstitial Fibrotic Disease; Transforming Growth Factor-β; Transcription; Plasminogen Activator Inhibitor-1; p53; Albany Medical College; (AMC); Ataxia Telangiectasia Mutated; (ATM); Center for Cell Biology &
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Beta–thromboglobulin; Ischemic stroke; Plasma; Plasminogen activator inhibitor-1; Tissue plasminogen activator
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; SA-βgal; senescence-associated β-galactosidase; SASP; senescence-associated secretory phenotype; FDA; Food and Drug Administration; GHRKO; growth hormone receptor knockout; ATTAC; apoptosis through targeted activation of caspase 8; BubR1; budding uninhi
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Dietary fats; Triacylglycerol; Cytokines; Metabolic syndrome; SFA; saturated fatty acids; MUFA; monounsaturated fatty acids; PUFA; polyunsaturated fatty acids; PAI-1; plasminogen activator inhibitor-1; iAUC; incremental area under the curve; TXB2; thrombo
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; acute lung injury; plasminogen activator inhibitor-1; nitric oxide; hyperoxia; fibrin;
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Asthma; Inhaled steroids; Smokers; Sputum mediators; Statins; ACQ; asthma control questionnaire; AQLQ; asthma quality of life questionnaire; ATS; American Thoracic Society; BMI; body mass index; CCL; chemokine (C-C motif) ligand; CXCL; chemokine (C-X-C mo
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; A488-FDP; AlexaFluor488-containing fibrin degradation products; AUC; area under curve; CCCP; carbonyl cyanide chlorophenylhydrazone; CR; clot retraction; CT; clotting time; DIC; disseminated intravascular coagulation; FITC; fluorescein isothiocyanate; GP;
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; ALT; alanine aminotransferase; AMPK; AMP-activated protein kinase; AST; aspartate aminotransferase; CDAA diet; choline-deficient/l-amino acid-defined diet; GLP-2; glucagon-like peptide-2; HFD; high fat diet; IL-1; interleukin 1; IL-6; interleukin 6; Fiaf;
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Metabolic syndrome; Adiponectin; Plasminogen Activator Inhibitor-1
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; PUC; Premature uterine contractions; PPROM; Preterm premature rupture of membranes; PTL; Preterm labor; aPTT; Activated partial thromboplastin time; PT; Prothrombin time; PT F1Â +Â 2; Prothrombin Fragments F1Â +Â 2; TAT; Thrombin anti thrombin; PAI 1; Pla
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Arginine supplementation; Dyslipidemia; Overweight; Resistance exercise; Plasminogen activator inhibitor-1;
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; n-3; omega-3; n-6; omega-6; PUFA; polyunsaturated fatty acids; PEPCK; phosphoenolpyruvate carboxykinase; G6Pase; glucose 6 phosphatase; ACC; acetyl-CoA carboxylase; FAS; fatty acid synthase; PMP-70; 70-kDa peroxisomal membrane protein; ACOX1; acyl-CoA oxi
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Exercise; Rehabilitation; Spinal cord injuries; AI; anthropometric index; BMI; body mass index; IL-6; interleukin-6; PAI-1; plasminogen activator inhibitor-1; SCI; spinal cord injury; TNF-α; tumor necrosis factor-alpha; VËo2max; maximum oxygen consumpti
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Antiphospholipid antibodies; Pathophysiology; Plasminogen activator; Plasminogen activator inhibitor-1; Protein S deficiency; Schizophrenia;
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; BMI; body mass index; ETP TM+/ETP TMâ; endogenous thrombin generation-in the presence/absence of soluble thrombomodulin; ETP; endogenous thrombin potential; ELISA; enzyme-linked immunosorbent assay; H3K4me3; H3 Lysine 4 trimethylated; H3K9ac; H3 Lysin
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Nattokinase; Cyclic adenosine monophosphate; Janus kinase1/signal transducers and activators of transcription1; Human umbilical vein endothelial cells; Tissue plasminogen activator; Plasminogen activator inhibitor-1;
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; cyanate; endothelial nitric oxide synthase; plasminogen activator inhibitor-1; renal disease; tissue factor;
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; Decorin; Lumican; Fibromodulin; Toll-like receptor; Matrix metalloproteinases; 5/6-Nx; 5/6-nephrectomized Sprague-Dawley rats; ADAMTS; a disintegrin and metalloproteinase with thrombospondin motifs; ALK; activin like kinase; ATS; hymocyte serum; BGN (Bgn)
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; ADAMTS1; ADAM metallopeptidase with thrombospondin type 1 motif, 1; ATP; adenosine triphosphate; APP; amyloid beta precursor protein; ANGPT2; angiopoietin 2; Ara-C; arabinosylcytosine; GBA; beta-glucocerebrosidase; BDNF; brain derived neurotrophic factor;
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; APHEA; Air Pollution and Health, a European Approach; BC; black carbon; BMI; body mass index; CHD; coronary heart disease; CO; carbon monoxide; CRP; C-reactive protein; DE; diesel exhaust; EDTA; ethylenediaminetetraacetic acid; ELISA; enzyme-linked immuno
Keywords: مهار کننده فعال کننده پلاسمینوژن-1; APTT; Activated partial thromboplastin time; ASIS; recombinant active site-inhibited factor VIIa; BD; brain dead; BSA; Bovine serum albumin; CCP; Cerebral perfusion pressure; CT; Clotting time; CTI; Corn trypsin inhibitor; ETP; endogenous thrombin potenti